The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HOLX | -8.61% | +7.4% | +1.44% | +2,992% |
| S&P | +19.89% | +109.18% | +15.89% | +1,956% |
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.02B | 1.2% |
| Gross Profit | $573.60M | 0.9% |
| Gross Margin | 56.03% | -0.2% |
| Market Cap | $14.52B | -16.2% |
| Market Cap / Employee | $2.06M | 0.0% |
| Employees | 7.1K | 0.0% |
| Net Income | $194.90M | 0.2% |
| EBITDA | $331.10M | -1.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.74B | -28.9% |
| Accounts Receivable | $609.30M | -3.1% |
| Inventory | 713.7 | 7.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.52B | 0.0% |
| Short Term Debt | $3.40M | -91.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.30% | -1.4% |
| Return On Invested Capital | 15.99% | 2.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $308.50M | -17.0% |
| Operating Free Cash Flow | $343.30M | -15.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 24.34 | 22.97 | 25.89 | 26.97 | 6.46% |
| Price to Book | 3.82 | 3.26 | 2.92 | 3.14 | -12.11% |
| Price to Sales | 4.73 | 4.17 | 3.44 | 3.63 | -17.58% |
| Price to Tangible Book Value | 19.44 | 19.83 | 25.01 | 45.25 | 108.93% |
| Price to Free Cash Flow TTM | 16.51 | 14.90 | 13.91 | 15.73 | -8.24% |
| Enterprise Value to EBITDA | 62.41 | 56.61 | 49.61 | 46.21 | -12.11% |
| Free Cash Flow Yield | 6.1% | 6.7% | 7.2% | 6.4% | 8.98% |
| Return on Equity | 15.6% | 15.8% | 11.8% | 11.4% | -17.83% |
| Total Debt | $2.66B | $2.54B | $2.53B | $2.52B | -1.43% |
HOLX earnings call for the period ending June 30, 2022.
HOLX earnings call for the period ending March 31, 2022.
HOLX earnings call for the period ending December 31, 2021.
HOLX earnings call for the period ending September 25, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
